profit from every $100 of sales.
$0$100
IM Cannabis
$0.57+2.75% today
-98.6% in 1 year
1-year low $0.551-year high $56.40
Trading close to its lowest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What IM Cannabis sold, what it kept, and what it did with the cash.
Sales went from CA$54.3 million in 2022 to CA$54.7 million in 2025, with -CA$11.3 million of profit last year.
SalesProfit
IM Cannabis vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| IM Cannabis | No profit yet | ||
 Merck KGaA | 24.9× · Fair price | ||
 Takeda Pharmaceutical | 102.5× · Very expensive | ||
 Galderma Group | 86.9× · Very expensive | ||
 Teva Pharmaceutical Industries | 36.8× · Expensive |
AI analysis
An AI analyst reads IM Cannabis's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of CAD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 54 | 49 | 54 | 55 | |
| 9 | 10 | 8 | 10 | |
| -23 | -12 | -10 | -12 | |
| -17 | -5 | -8 | -7 | |
| -189 | -9 | -11 | -11 | |
| -161.88 | -4.45 | -4.51 | -2.67 | |
| 16.9% | 20.2% | 15.6% | 17.7% | |
| -41.4% | -24.9% | -18.9% | -21.2% | |
| -347.6% | -19.5% | -19.6% | -20.7% |
Balance sheet
| In millions of CAD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 61 | 49 | 39 | 32 |
| Cash | 2 | 2 | 1 | 3 |
| Total debt | 12 | 14 | 18 | 16 |
| Total liabilities | 37 | 35 | 36 | 35 |
| 23 | 14 | 5 | -1 | |
| 1 | 2 | 2 | 4 | |
| -55.7% | -21.7% | -34.9% | -45.6% | |
| -833.9% | -65.6% | -201.9% | 1,319.2% |
Cash flow
| In millions of CAD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -13 | -8 | -1 | 5 | |
| 2 | 1 | 0 | 0 | |
| -14 | -9 | -1 | 5 | |
| Dividends paid | 0 | 0 | 0 | 0 |
| – | – | – | – | |
| 4 | 0 | 0 | 0 |
Valuation
- –
- –
- –
- 4.7×
- 0.0×
- 0.3×
- –
- 314.6%
- -757.1%
- 0.0%
Profitability
- 17.7%
- -21.2%
- -20.7%
- -1.0%
- -95.0%
- -142.6%
- -24.4%
- -2.8%
- -335.7%
- –
Growth
- +0.2%
- –
- +481.4%
- –
- +8.1%
Financial health
- –
- 4.44
- 38.1%
- -27.8×
- 0.72
- 0.62
- 0.94
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 1%of 952
Bottom 11%of 884
Bottom 18%of 886
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 13, 2026 | -0.28 | – | – |
| Mar 30, 2026 | -0.86 | 0.09 | −1,100.5% |
| Nov 13, 2025 | -0.54 | -0.02 | −2,234.6% |
| Aug 12, 2025 | -0.07 | -0.14 | +48.8% |
| May 15, 2025 | 0.06 | -0.25 | +123.6% |
| Mar 31, 2025 | -0.23 | -0.39 | +41.0% |
| Nov 14, 2024 | -0.30 | -0.70 | +57.1% |
| Aug 14, 2024 | -0.17 | -0.84 | +79.8% |
News
Tilray Just Posted Record Quarterly Revenue of $257 Million. So Why Did Its Cannabis Sales Shrink?Yahoo Finance · Nov 1, 2026Curaleaf challenge to Aurora Cannabis at-the-market program failsSeeking Alpha · Oct 26, 20262 High-Octane Cannabis Stocks to Buy in October for Aggressive InvestorsYahoo Finance · Oct 3, 2026The Cannabis M&A Wave Is Here. Curaleaf Proved It. Here's Whether Green Thumb Should Ride It -- or Wait to Be Swept Up.Yahoo Finance · Aug 23, 2026Is Curaleaf Stock a Buy With Its Attempted Hostile Takeover of Aurora Cannabis Under Way?Yahoo Finance · Aug 20, 2026Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
0/7Passes 0 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
17No pass
Benjamin Graham
2No pass
Philip Fisher
13No pass
Peter Lynch
0No pass
Joel Greenblatt
0No pass
Charlie Munger
13No pass
Terry Smith
12No pass
Questions about IM Cannabis
Is IM Cannabis a good stock to buy?
A business with weak numbers that is not profitable yet. 0 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the IM Cannabis AI analysis
What does IM Cannabis do?
IM Cannabis Corp. engages in breeding, growing, and supply of medical cannabis products in Israel, Germany, and Canada. It is in Drug Manufacturers - Specialty & Generic.
Does IM Cannabis pay a dividend?
No. IM Cannabis does not pay a dividend at the moment.
Is IM Cannabis stock halal?
No. IM Cannabis does not pass our halal screen: its debt is 1,088% of its market value, at or above the 33% limit. How we check
How has IM Cannabis stock done over the past year?
Down 98.6% over the past twelve months, to $0.57. It traded between $0.55 and $56.40 and is 99.0% below its high.
Who are IM Cannabis's competitors?
The largest listed companies in the same industry are Merck KGaA, Takeda Pharmaceutical, Galderma Group and Teva Pharmaceutical Industries. The peers table on this page compares their profit, growth and price with IM Cannabis's.
Prices: daily closes to Nov 13, 2026. Fundamentals: company reports via invest-like data.